The main purpose of this study is to determine if AZD8931 can improve the efficacy of
standard chemotherapy for the treatment of advanced breast cancer. This study will be
conducted in 2 parts: the first part (phase I) will determine a dose of AZD8931 that can be
safely administered with paclitaxel chemotherapy. The second part (phase II) will determine
the efficacy and safety of AZD8931 in combination with paclitaxel chemotherapy in breast
cancer.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Research Site, Brussels (Jette), Belgium
Research Site, Leuven, Belgium
Research Site, Namur, Belgium
Research Site, Sint-Niklaas, Belgium
Research Site, Sao Paulo, Brazil
Research Site, São Paulo, Brazil
Research Site, Sofia, Bulgaria
Research Site, Stara Zagora, Bulgaria
Research Site, Varna, Bulgaria
Research Site, Vratza, Bulgaria
Research Site, Brno, Czech Republic
Research Site, Jicin, Czech Republic
Research Site, Olomouc, Czech Republic
Research Site, Praha 2, Czech Republic
Research Site, Praha 4 - Krc, Czech Republic
Research Site, Praha 4, Czech Republic
Research Site, Znojmo, Czech Republic
Research Site, Villejuif Cedex, France
Research Site, Budapest, Hungary
Research Site, Debrecen, Hungary
Research Site, Györ, Hungary
Research Site, Szeged, Hungary
Research Site, Lido di Camaiore, Italy
Research Site, Modena, Italy
Research Site, Treviglio, Italy
Research Site, Ciudad de Panama, Panama
Research Site, Lima, Peru
Research Site, Barcelona, Spain
Research Site, Madrid, Spain
Research Site, Valencia, Spain
Research Site, Uppsala, Sweden
Research Site, Chur, Switzerland
Research Site, Glasgow, United Kingdom
Research Site, Leicester, United Kingdom
Research Site, London, United Kingdom
Research Site, Nottingham, United Kingdom
Research Site, Surrey, United Kingdom
Research Site, Halifax, Nova Scotia, Canada
Research Site, London, Ontario, Canada
Research Site, Ottawa, Ontario, Canada